PLUS THERAPEUTICS INC
PSTVNASDAQTrading Snapshot
- Day Range
- $3.82 – $3.93
- 52-Week Range
- $2.90 – $23.43
- Volume
- $1.94B
- Avg Volume
- $2.57B
- Shares Outstanding
- 2.4M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $411,000
- P/E Ratio
- -0.0
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-3.85
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1319516.7%
Why Investors Own PSTV
- ✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PLUS THERAPEUTICS INC
PSTV
StockOtter · stockotter.spaceAbout PLUS THERAPEUTICS INC
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10,
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics,
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agre
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages
Shares of Plus Therapeutics, Inc. (NASDAQ: PSTV - Get Free Report) have been given a consensus recommendation of "Hold" by the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst
Cerenome Launches as an Integrated CNS Oncology Company
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Comp